Both Ibrutinib and Acalabrutinib have been shown to decrease levels of CCL3 and CCL4, two critical chemokines inducing migration or homing of leukemia cells, in CLL-cell cultures and their separate clinical trials [14–16, 32]. The gene discussed is CCL4; the disease is B-cell chronic lymphocytic leukemia.